Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer

Cancer Research

Volumn 65, Issue 16, 2005, Pages 7081-7085

  Marsit, Carmen J ^a   Karagas, Margaret R ^b   Andrew, Angeline ^b   Liu, Mei ^a   Danaee, Hadi ^a   Schned, Alan R ^b   Nelson, Heather H ^a   Kelsey, Karl T ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRIZZLED PROTEIN; SECRETED FRIZZLED RECEPTOR PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; WNT1 PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER SURVIVAL; FEMALE; GENE; GENE INACTIVATION; GENE SILENCING; GENE TARGETING; GENETIC EPIGENESIS; GENETIC RISK; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL; SFRP GENE; SOLID TUMOR; TP53 GENE;

ADULT; AGED; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROMOTER REGIONS (GENETICS); PROTEINS; PROTO-ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 23844496681     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0267     Document Type: Article

References (22)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Abel PD, Hall RR, Williams G. Should pT1 transitional cell cancers of the bladder still be classified as superficial? Br J Urol 1988;62:235-9.
3. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-6.
4. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
5. Esrig D, Freeman JA, Stein JP, Skinner DG. Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol 1997;15:154-60.
6. Masters JH, Vani UD, Grigor KM, et al, Can p53 staining be used to identify patients with aggressive superficial bladder cancer? J Pathol 2003;200:74-81.
7. Muller T, Bain G, Wang X, Papkoff J. Regulation of epithelial cell migration and tumor formation by β-catenin signaling. Exp Cell Res 2002;280:119-33.
8. Barth AI, Nathke IS, Nelson WJ. Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways. Curr Opin Cell Biol 1997;9:683-90.
9. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36: 417-22.
10. Stoehr R, Wissmann C, Suzuki H, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004;84:465-78.
11. Karagas MR, Tosteson TD, Blum J, Morris JS, Baron JA, Klaue B. Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ Health Perspect 1998;106 Suppl 4:1047-50.
12. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
13. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
14. Kelsey KT, Hirao T, Schned A, et al. A population-based study of immunohistochemical detection of p53 alteration in bladder cancer. Br J Cancer 2004;90:1572-6.
15. Dyrskjot L, Kruhoffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004;64: 4040-8.
16. Kelsey KT, Hirao T, Hirao S, et al. TP53 alterations and patterns of carcinogen exposure in a US population-based study of bladder cancer. Int J Cancer. In press 2005.
17. Salem C, Liang G, Tsai YC, et al. Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res 2000;60:2473-6.
18. Stoehr R, Krieg RC, Knuechel R, et al. No evidence for involvement of β-catenin and APC in urothelial carcinomas. Int J Oncol 2002;20:905-11.
19. Toyooka S, Maruyama R, Toyooka KO, et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003;103:153-60.
20. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-24.
21. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003;4:351-8.
22. Friedrich MG, Weisenberger DJ, Cheng JC, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004;10:7457-65.